OLD National Bancorp IN Has $19.87 Million Stock Holdings in Danaher Co. (NYSE:DHR)

OLD National Bancorp IN reduced its stake in Danaher Co. (NYSE:DHR) by 0.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 71,474 shares of the conglomerate’s stock after selling 211 shares during the period. OLD National Bancorp IN’s holdings in Danaher were worth $19,871,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of DHR. Oak Thistle LLC acquired a new position in Danaher in the second quarter valued at about $363,000. Norden Group LLC bought a new stake in Danaher during the 1st quarter worth approximately $4,151,000. Duality Advisers LP acquired a new stake in Danaher during the 1st quarter valued at $5,573,000. Investment Research & Advisory Group Inc. bought a new position in Danaher in the 1st quarter valued at $1,186,000. Finally, Diversified Trust Co boosted its stake in Danaher by 75.4% in the second quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock worth $1,090,000 after purchasing an additional 1,874 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last ninety days. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $274.38 on Friday. The stock’s fifty day simple moving average is $270.72 and its 200 day simple moving average is $260.02. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $203.23 billion, a PE ratio of 46.51, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the business posted $2.05 EPS. Danaher’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, research analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is 18.31%.

Analysts Set New Price Targets

DHR has been the topic of several research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. TD Cowen raised their price target on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Evercore ISI upped their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Robert W. Baird lifted their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.